The 16 laboratories of GENOPATH sought to harmonize the molecular pathology evaluations underpinning the care of cancer patients within their respective regions. A key issue was to ensure that the laboratories nevertheless had a broad menu of molecular tests to choose from.
The GENOPATH molecular laboratory performs a broad spectrum of tumor panels from different suppliers. Especially in the analysis of complex workups, as is often the case with multi-gene panels like the TSO500, output data are interpreted with MH Guide. Thus, the oncologist network supported by GENOPATH receives a standardized and comprehensive interpretation of molecular tumor data and information about therapy options.
With up-to-date, comprehensive annotation of variants, each case evaluated by GENOPATH member laboratories results in an evidence-based decision about care for a patient. MH Guide enables harmonized data interpretation across laboratories and tests. Thus, the resulting reports are the basis for interactive discussions in the molecular tumor board to identify the best possible treatment, be it a targeted therapy or possibly participation in a clinical trial.